Suchergebnisse - "Makharadze, Tamta"

PubPharm (20)

1

Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312) : final results of a randomised phase 3 study

enthalten in: The lancet. Gastroenterology & hepatology | 2024

von Yau, T. | Kaseb, A. | Cheng, A. | +19

2

A global phase 3 study of serplulimab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (ASTRUM-004)

enthalten in: Cancer cell | 2024

von Zhou, C. | Hu, Y. | Arkania, E. | +24

CommentIn: Cancer Cell. 2024 Feb 12;42(2):172-174. - PMID 38350419

3

Quality of life with cemiplimab plus chemotherapy for first-line treatment of advanced non-small cell lung cancer : Patient-reported outcomes from phase 3 EMPOWER-Lung 3

enthalten in: Cancer | 2023

von Makharadze, T. | Quek, R. | Melkadze, T. | +16

4

Response to Letter to the Editor

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2023

von Makharadze, T. | Gogishvili, M. | Baramidze, A. | +7

5

Cemiplimab Plus Chemotherapy Versus Chemotherapy Alone in Advanced NSCLC : 2-Year Follow-Up From the Phase 3 EMPOWER-Lung 3 Part 2 Trial

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2023

von Makharadze, T. | Gogishvili, M. | Melkadze, T. | +17

CommentIn: J Thorac Oncol. 2023 Jul;18(7):e72-e73. - PMID 37348996

6

Candidate Bevacizumab Biosimilar CT-P16 versus European Union Reference Bevacizumab in Patients with Metastatic or Recurrent Non-Small Cell Lung Cancer : A Randomized Controlled Trial

enthalten in: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy | 2022

von Verschraegen, C. | Andric, Z. | Moiseenko, F. | +10

7

Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer : a randomized, controlled, double-blind phase 3 trial

enthalten in: Nature medicine | 2022

von Gogishvili, M. | Melkadze, T. | Makharadze, T. | +23

8

Candidate Bevacizumab Biosimilar CT-P16 versus European Union Reference Bevacizumab in Patients with Metastatic or Recurrent Non-Small Cell Lung Cancer: A Randomized Controlled Trial

enthalten in: BioDrugs | 2022

von Verschraegen, C. | Andric, Z. | Moiseenko, F. | +10

9

Candidate Bevacizumab Biosimilar CT-P16 versus European Union Reference Bevacizumab in Patients with Metastatic or Recurrent Non-Small Cell Lung Cancer: A Randomized Controlled Trial

enthalten in: BioDrugs | 2022

von Verschraegen, C. | Andric, Z. | Moiseenko, F. | +10

10

Candidate Bevacizumab Biosimilar CT-P16 versus European Union Reference Bevacizumab in Patients with Metastatic or Recurrent Non-Small Cell Lung Cancer: A Randomized Controlled Trial

enthalten in: BioDrugs | 2022

von Verschraegen, C. | Andric, Z. | Moiseenko, F. | +10